Steve Brachmann

Publish Date
Former USPTO Officials Urge Vidal to Immediately Withdraw NPRM on Terminal Disclaimers
IPWatchdog
Ex-USPTO Directors Want Vidal To Withdraw Disclaimer Plans
Law360
Quintet of Ex-Patent Office Officials Slam Proposed Rulemaking
Bloomberg Law
Fact Check: Price Controls Would Not Make Diabetes Treatments More Accessible

Bringing a new therapeutic to market is a challenging and costly endeavor. Strong intellectual property protections, which enable manufacturers to recoup their...

C4IP Urges Senate Judiciary to Ignore Common Myths About Drug Patents
IPWatchdog
Group chaired by former USPTO directors questions office’s AI guidance over ‘human contribution’
Inside AI Policy
Letters
C4IP Letter to Senate Judiciary Committee on 5/21 Hearing on Drug Prices

Dear Chairman Durbin and Ranking Member Graham: On behalf of the Council for Innovation Promotion (C4IP), we write in advance of your...

Industry Reacts to USPTO Guidance on Using AI to Innovate
JD Supra
Letters
C4IP Letter to Senate Commerce, Science, & Transportation Committee on the Invent Here, Make Here Act of 2023

Dear Chairwoman Cantwell and Ranking Member Cruz, The Council for Innovation Promotion (C4IP) writes to express its concerns about the unintended consequences...

USPTO Guidance On AI And Patents Draws Worry And Praise
Law360
Public Comments
C4IP Comments RE: Inventorship Guidance for AI-Assisted Inventions (PTO-P-2023-0043)
Inventor Spotlight: William Coolidge

This month, C4IP is recognizing William Coolidge, who transformed medicine with his invention of the modern X-ray. Coolidge was born in 1873...

News:

News:

Former USPTO Officials Urge Vidal to Immediately Withdraw NPRM on Terminal Disclaimers,

05/29/2024

News:

News:

Ex-USPTO Directors Want Vidal To Withdraw Disclaimer Plans,

05/28/2024

News:

News:

Quintet of Ex-Patent Office Officials Slam Proposed Rulemaking,

05/28/2024

Blog:

Blog, Fact Checks:

Fact Check: Price Controls Would Not Make Diabetes Treatments More Accessible,

05/24/2024

News:

News:

C4IP Urges Senate Judiciary to Ignore Common Myths About Drug Patents,

05/23/2024

News:

News:

Group chaired by former USPTO directors questions office’s AI guidance over ‘human contribution’,

05/21/2024

Resources:

Resources:

C4IP Letter to Senate Judiciary Committee on 5/21 Hearing on Drug Prices,

05/20/2024

News:

News:

Industry Reacts to USPTO Guidance on Using AI to Innovate,

05/20/2024

Resources:

Resources:

C4IP Letter to Senate Commerce, Science, & Transportation Committee on the Invent Here, Make Here Act of 2023,

05/15/2024

News:

News:

USPTO Guidance On AI And Patents Draws Worry And Praise,

05/14/2024

Resources:

Resources:

C4IP Comments RE: Inventorship Guidance for AI-Assisted Inventions (PTO-P-2023-0043),

05/13/2024

Blog:

Blog:

Inventor Spotlight: William Coolidge,

05/13/2024

Scroll to Top